Pancreatic Cancer

• KRAS mutations as initiating event: Activating mutations in the KRAS oncogene (codon 12, 13, or 61) occur in ~95% of PDAC cases and represent the earliest and most frequent alteration. These mutations constitutively activate downstream effector pathways (MAPK/ERK and PI3K/AKT cascades), driving uncontrolled cell proliferation, anchorage-independent growth, and metabolic reprogramming. KRAS-driven signaling promotes increased glucose and glutamine utilization, supporting the aggressive phenotype while simultaneously activating autocrine TGF-β signaling that promotes fibroblast activation and collagen deposition.

• Progressive inactivation of tumor suppressors (p53, SMAD4, CDKN2A/p16): Following KRAS activation, loss of function mutations in TP53 (occurring in ~50-70% of cases) eliminate apoptotic checkpoints and genomic instability safeguards, permitting further clonal evolution. SMAD4 loss (present in ~30% of tumors) disrupts TGF-β signaling's growth-inhibitory functions while paradoxically enhancing stromal desmoplasia. CDKN2A/p16 inactivation (present in ~80-95% of cases, frequently through promoter methylation) removes G1/S checkpoint control, allowing uncontrolled cell cycle progression. The sequential acquisition of these alterations, typically requiring 15-20 years, correlates with progression through pancreatic intraepithelial neoplasia (PanIN) grades 1-3 to invasive carcinoma.

• Epithelial-mesenchymal transition (EMT) and stromal interaction: Tumor cells activate EMT programs through loss of E-cadherin expression and gain of mesenchymal markers (vimentin, N-cadherin), enabling invasive capacity and lymphovascular invasion. The dense desmoplastic stroma surrounding PDAC comprises cancer-associated fibroblasts (CAFs), myofibroblasts, and extensive extracellular matrix deposition that paradoxically creates a barrier to drug penetration while simultaneously providing growth factors (FGF, HGF) and pro-inflammatory cytokines (IL-1, IL-6, IL-8) supporting tumor progression. Pancreatic stellate cells, activated by tumor-derived cytokines, differentiate into myofibroblasts and produce collagen I/III, creating the characteristic hypovascular, fibrotic microenvironment that limits blood perfusion and facilitates local invasion.

• Perineural invasion (PNI) and neuroplasticity: PDAC exhibits distinctive PNI with tumor cells tracking along nerve fibers, correlating with poor prognosis and pain symptoms. Nerve fibers provide trophic support through secretion of neurotrophic factors (particularly nerve growth factor, NGF), while tumor-derived neurotrophins (GDNF, BDNF) promote nerve expansion and sprouting. This bidirectional crosstalk facilitates both local tumor spread and metastatic dissemination; perineural projections represent a major route of early spread to regional lymph nodes and distant sites, explaining the advanced stage at presentation.

• Genomic instability and metastatic competence: Beyond driver mutations, PDAC exhibits widespread chromosomal instability with aneuploidy, frequent DNA damage, and dysregulation of homologous recombination repair genes (BRCA1/2 mutations in ~5-7% of cases). This genomic instability paradoxically provides evolutionary flexibility, enabling rapid acquisition of metastatic properties including resistance to chemotherapy. Early dissemination of cancer cells to distant organs occurs before the primary tumor reaches detectable size, with circulating tumor DNA detectable in many patients at diagnosis. Metastatic seeding preferentially establishes in the liver (~80% of metastatic cases) and peritoneum, facilitated by high expression of chemokine receptors (CXCR4) and selectins mediating organ tropism.

• Metabolic reprogramming and immune evasion: PDAC cells exhibit profound metabolic alterations including enhanced glycolysis (Warburg effect) and glutamine addiction, driven by KRAS signaling and facilitating survival in the nutrient-poor tumor microenvironment. The acidic microenvironment from lactate accumulation promotes MDSC and regulatory T cell (Treg) differentiation, creating immunosuppression. Additionally, PDAC exhibits low mutational burden and minimal MHC class I expression, features that render standard checkpoint inhibitors ineffective as monotherapy and explain the remarkably "cold" immune microenvironment.

• Chronic pancreatitis: Chronic pancreatitis increases pancreatic cancer risk 20-50 fold, with cumulative incidence reaching 5-10% over 20 years of disease. The mechanism involves persistent inflammation with increased oxidative stress, repeated cycles of acinar cell injury and regeneration, and promotion of PanIN development. Both alcohol-related and idiopathic chronic pancreatitis confer similar risk; the duration and severity of inflammation correlate with malignant transformation risk.

• Hereditary syndromes: Multiple hereditary conditions predispose to PDAC with varying penetrance. Lynch syndrome (mismatch repair gene mutations) confers 8-10 fold increased risk. Hereditary breast and ovarian cancer syndrome from BRCA1/2 mutations increases risk approximately 2-7 and 3-10 fold, respectively, with penetrance increasing with age. Familial adenomatous polyposis (FAP) from APC mutations increases risk 10-100 fold. Peutz-Jeghers syndrome (STK11/LKB1 mutations) carries extremely high risk (60-70% lifetime risk). Familial atypical multiple mole melanoma (FAMMM) syndrome from p16/CDKN2A mutations increases risk 20-40 fold. Hereditary pancreatitis from PRSS1 mutations increases risk 40-50 fold. First-degree relatives of PDAC patients show 1.5-3 fold increased risk, particularly if two or more relatives are affected (hereditary predisposition).

• Cigarette smoking: Active smoking increases risk 2-3 fold with dose-dependent relationship; former smokers retain elevated risk for years. Smoking promotes carcinogenic nitrosamine formation and directly activates KRAS mutations. Secondhand smoke exposure also increases risk approximately 1.5 fold.

• Obesity and diabetes mellitus: Obesity (BMI >30) increases risk approximately 1.5-2 fold through promotion of chronic inflammation, insulin resistance, and altered adipokine signaling. Type 2 diabetes mellitus increases risk 1.5-2 fold, though new-onset diabetes within 1-3 years of presentation warrants elevated suspicion for pancreatic cancer; this "diabetes unmasking syndrome" reflects cancer-induced metabolic derangement rather than causation. Type 1 diabetes shows minimal risk elevation.

• Alcohol consumption: Moderate to heavy alcohol consumption increases risk 1.5-2 fold, primarily through promotion of chronic pancreatitis rather than direct carcinogenesis. The relationship is less strong than for smoking; heavy alcohol use in the setting of chronic pancreatitis carries compounded risk.

• Smoking and alcohol synergy: Combined smoking and alcohol use demonstrate multiplicative rather than additive risk elevation, suggesting mechanistic overlap in carcinogenesis.

• Occupational/environmental exposures: Chronic exposure to certain chemicals (pesticides, solvents, asbestos) in occupational settings increases risk modestly (approximately 1.5-2 fold). Previous abdominal radiation (particularly for lymphoma or gynecologic malignancies) increases risk, with dose-dependent relationship.

• Diet and lifestyle factors: High intake of red and processed meats increases risk approximately 1.5 fold. Consumption of vegetables and fruits shows protective association. Regular physical activity shows inverse correlation with risk.

• Painless jaundice (head/uncinate process tumors): Jaundice represents the most common presenting symptom (occurring in 60-70% of patients with head location) and reflects obstruction of the common bile duct by tumor mass or involvement. Bilirubin accumulation (typically >3 mg/dL to produce clinically apparent jaundice) creates characteristic pale, clay-colored stools from absent bile pigment and dark tea-colored urine from conjugated bilirubinuria. Pruritus develops from bile salt deposition in skin, sometimes preceding visible jaundice. Notably, jaundice from pancreatic head cancer is typically painless in distinction from biliary obstruction, though concurrent pain from perineural invasion occurs in 30-40% of patients. The pattern of painless jaundice with progressive intensification should immediately raise suspicion for malignancy. Cholangitis develops if complete obstruction promotes bacterial overgrowth and increased intraluminal pressure; fever, jaundice, and right upper quadrant pain constitute Charcot's triad signaling infectious complication requiring urgent intervention.

• Abdominal and back pain (body/tail tumors): Pain occurs as the presenting symptom in 40-50% of cases, particularly in body and tail locations where tumors often achieve larger size before detection. The pain quality reflects perineural invasion and retroperitoneal involvement, classically described as epigastric or left upper quadrant pain radiating to the back. The pain is typically progressive, severe, boring in quality, and frequently disrupts sleep; it often worsens when supine and may be partially relieved by forward flexion. Onset of new upper abdominal or back pain in the setting of constitutional symptoms and weight loss warrants imaging evaluation. Pain from retroperitoneal involvement carries particularly poor prognostic implications and may respond poorly to opioids, necessitating early multimodal pain management including pancreatic plexus block consultation.

• Weight loss and constitutional symptoms: Unintentional weight loss (>10 pounds in preceding 3-6 months) occurs in 80-90% of patients and reflects metabolic derangement from cancer burden and altered satiety signaling. The weight loss is typically rapid and refractory to nutritional intervention. Anorexia, fatigue, and malaise are nearly universal in advanced disease. Cancer cachexia involves loss of skeletal muscle mass disproportionate to fat loss, driven by tumor-secreted inflammatory cytokines (IL-6, TNF-α) and metabolic dysfunction. These symptoms often precede objective imaging findings, making clinical vigilance for this constellation in high-risk patients critical.

• New-onset diabetes mellitus or glycemic deterioration: Approximately 50% of PDAC patients have diabetes at diagnosis, with ~25% representing newly diagnosed disease. The "diabetes unmasking syndrome" describes new-onset diabetes occurring within 1-3 years preceding cancer diagnosis. The mechanism involves direct infiltration of pancreatic islets and paraneoplastic β-cell dysfunction from tumor-derived cytokines. Conversely, sudden deterioration in glycemic control in long-standing diabetics warrants pancreatic imaging to exclude occult malignancy, particularly with concomitant weight loss and pain.

• Nausea, vomiting, and gastric outlet obstruction: Tumors in the head region may compress or invade the duodenum, causing mechanical gastric outlet obstruction. Patients report postprandial nausea, vomiting undigested food, early satiety, and progressive inability to maintain oral intake. Duodenal involvement may also promote autoimmune gastritis-like phenomena. Additionally, metabolic dysfunction and chemotherapy-related effects contribute to nausea even without mechanical obstruction.

• Steatorrhea and pancreatic insufficiency: Pancreatic parenchymal invasion causes chronic pancreatitis-like changes with loss of exocrine function. Steatorrhea (fatty, pale, foul-smelling stools) reflects impaired fat digestion from lipase deficiency. Pancreatic insufficiency develops gradually, though often overshadowed by other presenting symptoms. Cobalamin (B12) deficiency may develop from pancreatic insufficiency reducing intrinsic factor availability.

• Ascites and peritoneal involvement: Peritoneal metastases occur in 40-50% of advanced cases, causing ascites with characteristic "pancreatic cancer ascites" rich in tumor cells and inflammatory exudate. Ascites development reflects both decreased albumin synthesis from hepatic metastases and increased peritoneal vascular permeability from inflammation. Peritoneal carcinomatosis may present acutely with bowel obstruction from tumor nodules and adhesions.

• Physical examination findings: Hepatomegaly is present in 30-50% (from hepatic metastases), often with irregular, hard hepatic edge. Palpable abdominal mass suggests advanced local disease (present in only 15-20%). Supraclavicular lymphadenopathy indicates distant metastatic spread. Courvoisier sign (palpable, non-tender gallbladder in the setting of jaundice) is traditionally associated with pancreatic cancer causing CBD obstruction; positive predictive value is ~80% in this context, though more commonly observed with distal CBD stones. Ascites indicates advanced peritoneal involvement with poor prognosis. Left supraclavicular node enlargement (Virchow node) suggests metastatic disease. Jaundice with hepatomegaly and ascites creates the triad of advanced malignancy.

• Atypical presentations: Left pleural effusion occurs from hematogenous metastases or peridiaphragmatic involvement. Acute pancreatitis may represent the presenting illness if tumor obstructs the pancreatic duct, elevating amylase and lipase without explaining the imaging findings. Thrombophlebitis (particularly migratory) can represent a paraneoplastic phenomenon, reflecting tumor-derived procoagulant activity. Depression and psychiatric symptoms sometimes precede detection of pancreatic cancer through unclear mechanisms. Acute hepatic decompensation in a patient with previously stable liver disease may reflect rapid hepatic metastatic burden.

• Clinical suspicion and history: Diagnosis begins with maintaining appropriate clinical suspicion in the setting of jaundice, new abdominal or back pain, unintentional weight loss (particularly >10 lbs in 3-6 months), or new-onset diabetes in patients >40 years old. Historical risk factors should be actively elicited: smoking and alcohol history, family history of pancreatic cancer or hereditary syndromes (BRCA mutations, Lynch syndrome, Peutz-Jeghers), chronic pancreatitis history, and constitutional symptoms. Duration and character of symptoms guide differential diagnosis; painless jaundice with progressive bilirubin elevation in head tumors differs from progressive epigastric pain in body/tail tumors.

• Serum bilirubin and liver function tests: Direct (conjugated) hyperbilirubinemia >3 mg/dL develops from CBD obstruction; the degree of elevation correlates loosely with obstruction severity. Alkaline phosphatase and gamma-glutamyl transferase elevation accompany biliary obstruction, typically exceeding aminotransferase elevation (obstructive pattern). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation usually <4 fold occurs from hepatic metastases or cholestasis. Remarkably, liver function tests may be entirely normal in body/tail tumors without biliary involvement, necessitating imaging based on clinical suspicion alone. The development of Paget-Scrötter syndrome (thrombophlebitis of the upper extremity with characteristic asymmetry) warrants pancreatic imaging given its association with PDAC.

• CA 19-9 tumor marker: CA 19-9 (carbohydrate antigen 19-9) is a sialylated Lewis antigen-derived glycoprotein with sensitivity 80-90% and specificity 90-95% for PDAC in symptomatic patients. Baseline level >1,000 U/mL suggests advanced disease; levels <20 U/mL carry better prognosis. Importantly, CA 19-9 may be falsely elevated in benign conditions (cholangitis, biliary obstruction, cirrhosis, gast

Immediate stabilisation

• Biliary decompression: symptomatic obstructive jaundice or ascending cholangitis is managed with ERCP and stent placement — a self-expanding metal stent when neoadjuvant therapy or palliation is planned, since plastic stents occlude quickly. Cholangitis requires urgent drainage plus IV antibiotics; percutaneous transhepatic drainage is the fallback when ERCP fails.
• Supportive care: pancreatic enzyme replacement for exocrine insufficiency, opioid analgesia with early consideration of celiac plexus neurolysis for boring back pain, and anticoagulation for the high baseline VTE risk. ASCO recommends early integration of palliative care alongside cancer-directed therapy.

Definitive/surgical management

• Resection: pancreaticoduodenectomy (Whipple) for head/uncinate tumours; distal pancreatectomy with splenectomy for body/tail. Only a minority of patients are candidates.
• Adjuvant chemotherapy: modified FOLFIRINOX (5-FU/leucovorin, irinotecan, oxaliplatin) for fit patients after resection (PRODIGE-24); gemcitabine plus capecitabine or gemcitabine alone for lesser performance status.
• Borderline resectable/locally advanced: neoadjuvant systemic chemotherapy ± chemoradiation, with restaging before any attempt at resection.

Metastatic and second-line therapy

• First line: FOLFIRINOX for ECOG 0–1; gemcitabine plus nab-paclitaxel as the alternative doublet; gemcitabine monotherapy for frail patients.
• Second line: switch backbones — liposomal irinotecan with 5-FU/leucovorin after gemcitabine-based therapy, or a gemcitabine-based regimen after FOLFIRINOX.
• Biomarker-directed: platinum-based therapy for germline BRCA1/2 with maintenance PARP inhibitor (olaparib); pembrolizumab for MSI-high/dMMR tumours; TRK inhibitors for NTRK fusions.

Contraindicated / avoid

• Resection in metastatic disease or arterial encasement: no survival benefit; surgery is palliative at best.
• Checkpoint inhibitor monotherapy in microsatellite-stable disease: the immunologically cold stroma makes it ineffective.
• Routine preoperative biliary stenting in resectable, non-cholangitic patients: increases perioperative infectious complications.
• Population screening: USPSTF recommends against screening asymptomatic average-risk adults.

Disease-related — emergencies flagged

• Ascending cholangitis (EMERGENCY): complete biliary obstruction permits bacterial overgrowth under pressure with bacteraemia; Charcot triad (fever, jaundice, RUQ pain) or Reynolds pentad with hypotension and confusion signals it. Requires IV antibiotics and urgent biliary drainage.
• Venous thromboembolism / Trousseau syndrome (EMERGENCY if PE): tumour-derived tissue factor and mucins generate a hypercoagulable state; migratory superficial thrombophlebitis, unexplained DVT, or sudden dyspnoea and hypoxaemia are the clues. ASCO's VTE guideline supports LMWH or a direct oral anticoagulant over warfarin.
• Gastric outlet obstruction: duodenal invasion or extrinsic compression; vomiting of undigested food with early satiety and a succussion splash. Managed by enteral stenting or gastrojejunostomy.
• Exocrine insufficiency and cachexia: lipase deficiency and ductal obstruction produce steatorrhea, fat-soluble vitamin deficiency, and weight loss refractory to feeding; cytokine-driven muscle wasting compounds it.
• Endocrine failure: islet destruction causes new or worsening hyperglycaemia; a sudden loss of glycaemic control in an older diabetic is the classic signal.
• Malignant ascites and malignant bowel obstruction: peritoneal carcinomatosis; increasing girth, positive cytology, colicky pain with obstipation.
• Intractable pain from perineural/celiac plexus invasion: opioid-refractory boring back pain relieved by leaning forward.

Treatment-related

• Postoperative pancreatic fistula: leak from the pancreaticojejunal anastomosis; amylase-rich drain output persisting beyond the third postoperative day.
• Post-pancreatectomy haemorrhage (EMERGENCY): fistula erodes into the gastroduodenal artery stump; a sentinel bleed from the drain or NG tube precedes exsanguination — CT angiography and angioembolisation.
• Delayed gastric emptying: the most frequent Whipple complication; prolonged nasogastric requirement without mechanical obstruction.
• Brittle diabetes and permanent exocrine failure: after total or extensive pancreatectomy.
• Post-splenectomy sepsis: encapsulated organisms after distal pancreatectomy; requires vaccination per CDC/ACIP.
• Chemotherapy toxicity: febrile neutropenia (EMERGENCY), irinotecan-induced diarrhoea (worse with UGT1A1 polymorphisms), oxaliplatin cold-triggered peripheral neuropathy, gemcitabine myelosuppression.
• Biliary stent occlusion: recurrent jaundice or cholangitis months after placement.

• Painless jaundice + Courvoisier sign + weight loss in an adult over 60: pancreatic head adenocarcinoma until proven otherwise. A palpable, non-tender gallbladder argues against stones, which scar the gallbladder and prevent distension.
• Best next step: after right upper quadrant ultrasound in a jaundiced patient, the definitive imaging study is a pancreas-protocol multiphase contrast-enhanced CT — it both makes the diagnosis and answers the only question that changes management, resectability (NCCN). CT precedes any biopsy.
• Tissue diagnosis is not required before resection of a clearly resectable mass, because a negative FNA cannot exclude cancer; it is required before neoadjuvant chemotherapy. When biopsy is needed, EUS-guided FNA beats a percutaneous route (lower seeding risk, better nodal staging).
• CA 19-9 is not a screening or diagnostic test: it is a Lewis antigen–based glycoprotein used for prognosis and treatment monitoring. Biliary obstruction, cholangitis, and cirrhosis raise it falsely, and Lewis antigen–negative individuals never produce it at all — a favourite distractor.
• The genetics examiners test: KRAS activation is the near-universal initiating mutation; SMAD4 (DPC4) loss and CDKN2A/p16 inactivation are the other classics. Germline BRCA1/2 matters clinically because it predicts platinum sensitivity and eligibility for maintenance PARP inhibition.
• Trousseau syndrome: migratory superficial thrombophlebitis in odd locations is a paraneoplastic clue; treat with LMWH or a DOAC, not warfarin (ASCO).
• New-onset diabetes plus weight loss in an older adult should prompt pancreatic imaging — the association is directional (cancer causing the diabetes), and this appears repeatedly in stems.
• Common distractors: do not screen the general population (USPSTF grade D); do not offer resection for arterially encased or metastatic disease; and do not confuse Whipple (head/uncinate) with distal pancreatectomy plus splenectomy (body/tail). Ampullary and duodenal cancers jaundice earlier and carry a better prognosis than PDAC.